The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

“…(D) The level of REST dramatically reduced in differentiated SH-SY5Y cells treated with GA (1 μM) or PU-H71 (50 nM) at 24 h. (E) The REST level decreased by GA more than 50% and (F) PU-H71 more than 80%, respectively. …”

CHAPb Tg mice show decrease cardiac performance. by Willemijn van Eldik (4662955)

B-THP-Ts decrease cellular ATP levels. by Lindsay B. Tulloch (1266861)

Decrease of autoantibody levels in highly inflammatory NSG mice. by Henrika Jodeleit (4722312)

DataSheet_2_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

“…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”

DataSheet_1_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

“…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”

Transaldolase deficiency causes a starvation-like response that decreases animal fat content and rewires lipid metabolism gene expression. by Christopher F. Bennett (3875731)

“…<p><b>(A)</b> Intestinal fat staining decreases from RNAi knockdown of <i>tald-1</i> or <i>cco-1</i>. …”

Ade decreases cell viability and induces cell death. by Shujue Li (466324)

Calyculin A-induced decrease of tyrosine-monophosphorylated ERK2 at high cell density. by Noriyuki Kawabata (3391739)

Effects of siRNA TMPRSS2-ERG on ERG protein expression and cell viability. by Giorgia Urbinati (554921)

“…<p>VCaP cells were transfected for 24h, 48h and 72h with 50 nM of siRNAs TMPRSS2-ERG III (1, 2, 3), siRNAs TMPRSS2-ERG IV (1, 2), siRNA against ERG wild type or siRNA Control. …”

Decreased fibrin deposition in hypoxic C3−/− mice. by Eileen M. Bauer (337320)

MPI knockdown decreases migration of human glioblastoma cells. by Aurélie Cazet (644004)

Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

“…Scale: 500 pA, 100 ms. <b>B</b>. I–V curves showing a significant decrease in Kv amplitude in PV interneurons from mice that underwent juvenile demyelination. …”

Effects of siRNA TMPRSS2-ERG III and IV on cell death pathways. by Giorgia Urbinati (554921)

Memory defects, decreased anxiety, and increased social interaction. by Annette E. Rünker (195285)

“…NOR performance at the 4-hr retention interval did not differ from chance (50%) across the genotypes. (C) Spontaneous alternation test of working memory revealed a sex-specific deficit in working memory performance in <i>Sema6A^−/−</i> males (n = 8), as indicated by a decrease in percent alternation, relative to controls (n = 10; p<0.01). …”

Growth on stiff substrate results in mild lifespan extension but a decrease in organismal health. by Maria Oorloff (19658113)

ATRA improved vimentin organization and decreased its expression. by Carmen Retana (479628)

Que decreases the number of infiltrating T cells in spinal cord. by Feng Mei (143817)

“…<b>E–G</b>: CD8⁺ cells display a similar decrease after Que treatment (N = 5, *, <i>p<</i>0.05), but the overall extent of CD8⁺ cells detected was much less than that of CD4⁺ cells. …”

Trehalose decreased PAN-induced apoptosis in human podocytes. by Yu-Lin Kang (663806)

“…<p>Podocyte were treated with PAN (30 µg/ml) or/and Trehalose (50 mM) for 48 h. (<b>A</b>) Trehalose induced autophagy in PAN-treated human podocytes. …”

Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

“…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”